Lactonic sophorolipid由槐糖基与长链羟基脂肪酸通过内酯键构成，兼具细胞毒性效应和表面活性特性。
Cas No.:148409-20-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Lactonic sophorolipid is made up of a sophorose moiety attached to a long chain of hydroxyl fatty acid, with cytotoxic effects and surface-active properties[1]. Lactonic sophorolipid exerts bacteriostatic and bactericidal effects by disrupting the cell wall, increasing the permeability of the cell membrane, and causing the efflux of intracellular substances[2]. Lactonic sophorolipid has been widely used to inhibit oral pathogens both in planktonic and oral biofilm states[3].
In vitro, Lactonic sophorolipid treatment for 24 hours significantly inhibited the viability of HepG2 cells, with an IC50 value of 25μg/ml[4]. Lactonic sophorolipid treatment at 6mg/ml for 4 hours significantly hindered the synthesis of the cell wall of Pseudomonas aeruginosa, resulting in a decrease in the ATP content of the bacteria and inhibition of bacterial growth[5].
In vivo, Lactonic sophorolipid treatment via oral administration at a dose of 50mg/kg (every other day for 70 days) significantly increased the number and size of intestinal polyps in Apcmin+/- mice[6].
References:
[1] Van Bogaert I N A, Saerens K, De Muynck C, et al. Microbial production and application of sophorolipids[J]. Applied microbiology and biotechnology, 2007, 76(1): 23-34.
[2] Cho W Y, Ng J F, Yap W H, et al. Sophorolipids—bio-based antimicrobial formulating agents for applications in food and health[J]. Molecules, 2022, 27(17): 5556.
[3] Elshikh M, Moya‐Ramírez I, Moens H, et al. Rhamnolipids and lactonic sophorolipids: natural antimicrobial surfactants for oral hygiene[J]. Journal of applied microbiology, 2017, 123(5): 1111-1123.
[4] Wang X, Xu N, Li Q, et al. Lactonic sophorolipid–induced apoptosis in human HepG2 cells through the Caspase-3 pathway[J]. Applied Microbiology and Biotechnology, 2021, 105(5): 2033-2042.
[5] Ma X, Wang T, Zhang H, et al. Comparison of inhibitory effects and mechanisms of lactonic sophorolipid on different pathogenic bacteria[J]. Frontiers in Microbiology, 2022, 13: 929932.
[6] Callaghan B, Lydon H, Roelants S L K W, et al. Lactonic sophorolipids increase tumor burden in Apcmin+/-mice[J]. PloS one, 2016, 11(6): e0156845.
Lactonic sophorolipid由槐糖基与长链羟基脂肪酸通过内酯键构成，兼具细胞毒性效应和表面活性特性[1]。Lactonic sophorolipid通过破坏细胞壁、增加细胞膜通透性及引发胞内物质外流，发挥抑菌和杀菌作用[2]。Lactonic sophorolipid已广泛应用于抑制浮游状态和口腔生物膜状态下的口腔致病菌生长[3]。
在体外，Lactonic sophorolipid处理24小时可显著抑制HepG2细胞活力，IC50值为25μg/ml[4]。使用6mg/ml的Lactonic sophorolipid处理铜绿假单胞菌4小时，能显著阻碍细胞壁合成，导致细菌ATP含量下降并抑制细菌生长[5]。
在体内，隔日口服50mg/kg剂量的Lactonic sophorolipid连续70天，可显著增加Apcmin+/-小鼠肠道息肉的数量和大小[6]。
| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation Method | HepG2 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin, and 100μg/ml streptomycin. Cells were cultured in an incubator at 37°C with 5% CO2. HepG2 cells (1×104 cells/well) were seeded in 96-well plates and cultured with Lactonic sophorolipid at different concentrations (2.5, 5, 10, 20, 40, 80, and 160μg/ml) in complete medium for 24, 48, and 72 hours. During the last 4h of incubation, MTT (5mg/ml) was added to each well, and DMSO was added to dissolve the crystals before absorbance was measured at a wavelength of 490nm. |
Reaction Conditions | 2.5, 5, 10, 20, 40, 80, and 160μg/ml; 24, 48, and 72h |
Applications | Lactonic sophorolipid treatment inhibited the viability of HepG2 cells in a dose- and time-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Apcmin+/- mice |
Preparation Method | Male Apcmin+/- mice were housed under 12/12h light/dark cycles and had ad libitum access to food and water. Every other day, mice were orally administered vehicle solution or 0.1% ethanol/10% sucrose solution containing 50mg/kg Lactonic sophorolipid (using a sterile p20 pipet tip). The whole experiment lasted for 70 days and, histopathological changes in the intestine were evaluated. |
Dosage form | 50mg/kg; every other day for 70 days; p.o. |
Applications | Lactonic sophorolipid treatment significantly resulted in an increase in the number and size of intestinal polyps in mice. |
References: | |
| Cas No. | 148409-20-5 | SDF | |
| 别名 | 槐糖脂 | ||
| Canonical SMILES | O=C1CCCCCCC/C=C/CCCCCC[C@H](C)O[C@]2([H])O[C@H](COC(C)=O)[C@@H](O)[C@H](O)[C@@]2([H])O[C@@](O[C@@H]3COC(C)=O)([H])[C@H](O)[C@@H](O)[C@]3([H])O1 | ||
| 分子式 | C34H56O14 | 分子量 | 688.8 |
| 溶解度 | DMF: 30 mg/mL,DMSO: 30 mg/mL,Ethanol: 30 mg/mL,Ethanol:PBS (pH 7.2) (1:4): 0.2 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4518 mL | 7.259 mL | 14.518 mL |
| 5 mM | 290.4 μL | 1.4518 mL | 2.9036 mL |
| 10 mM | 145.2 μL | 725.9 μL | 1.4518 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >80.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet